project year

2026

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors

Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

Predicting clinical response to breast cancer therapy – the immune signature approach

Resolving prostate cancer: Elucidating the epigenetics of tumour microenvironment cells to advance understanding of disease aetiology and improve patient diagnosis

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy

Help us to put an end to cancer